{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:03:50Z","timestamp":1792512230938,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>Few treatments are available for patients with mood disorders or post-traumatic stress disorder (PTSD) who have already failed multiple interventions. After several decades when research into psychedelics was effectively halted by federal legislation, the past several years have shown the re-emergence of thoughtful investigations studying the utility of compounds such as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>Several studies have coupled the safe administration of psychedelic compounds in a controlled environment after several hours of preparation of study participants and followed by multiple sessions to integrate the psychedelic experience. The improvement participants experience appear related to the often profound perspective changes experienced and seem unlike the improvements seen in the currently available care paradigms. Studies cited include treatment resistant depression, end of life despair, and PTSD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Psychedelic psychotherapy, a unique remarriage of biological therapy and psychotherapy, has the potential to transform mental health care.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11920-022-01363-y","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T08:03:23Z","timestamp":1663747403000},"page":"583-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["The Emerging Field of Psychedelic Psychotherapy"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-8098","authenticated-orcid":false,"given":"Gregory S.","family":"Barber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Aaronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"1363_CR1","unstructured":"WHO. Depression and other common mental disorders.\u00a02017. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254610\/WHO-MSD-MER-2017.2-eng.pdf"},{"issue":"13","key":"1363_CR2","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1017\/S0033291717000708","volume":"47","author":"KC Koenen","year":"2017","unstructured":"Koenen KC, Ratanatharathorn A, Ng L, et al. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol Med. 2017;47(13):2260\u201374. https:\/\/doi.org\/10.1017\/S0033291717000708.","journal-title":"Psychol Med"},{"key":"1363_CR3","unstructured":"Jacobs A. The psychedelic revolution is coming. psychiatry may never be the same. The New York Times. Published 2021. https:\/\/www.nytimes.com\/2021\/05\/09\/health\/psychedelics-mdma-psilocybin-molly-mental-health.html?action=click&module=Top_Stories&pgtype=Homepage"},{"key":"1363_CR4","unstructured":"Eschner K. The promises and perils of psychedelic health care. The New York Times. 2022."},{"key":"1363_CR5","unstructured":"Pollan M. How to Change Your Mind. Penguin Books.\u00a02018."},{"key":"1363_CR6","unstructured":"Schwartzberg L. Fantastic Fungi.\u00a02019."},{"key":"1363_CR7","unstructured":"Angell T. AOC pushes to make it easier to study shrooms and other psychedelic drugs. Forbes. Published 2019. https:\/\/www.forbes.com\/sites\/tomangell\/2019\/06\/08\/aoc-pushes-to-make-it-easier-to-study-shrooms-and-other-psychedelic-drugs\/?sh=5eeeccd51002"},{"key":"1363_CR8","unstructured":"Svitek P. Rick Perry returns to the Texas Capitol to pitch study of psychedelic drugs for PTSD in veterans. The Texas Tribune. Published 2021. https:\/\/www.texastribune.org\/2021\/04\/13\/veterans-ptsd-psychedelics-texas\/"},{"issue":"11","key":"1363_CR9","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","volume":"42","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017;42(11):2105\u201313. https:\/\/doi.org\/10.1038\/npp.2017.84.","journal-title":"Neuropsychopharmacology"},{"key":"1363_CR10","doi-asserted-by":"publisher","first-page":"205032451876744","DOI":"10.1177\/2050324518767442","volume":"4","author":"T Passie","year":"2018","unstructured":"Passie T. The early use of MDMA (\u2018Ecstasy\u2019) in psychotherapy (1977\u20131985). Drug Sci Policy Law. 2018;4:205032451876744. https:\/\/doi.org\/10.1177\/2050324518767442.","journal-title":"Drug Sci Policy Law"},{"issue":"5","key":"1363_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177(5):391\u2013410. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19010035.","journal-title":"Am J Psychiatry"},{"issue":"21","key":"1363_CR12","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1007\/s00213-014-3570-x","volume":"231","author":"MC Wardle","year":"2014","unstructured":"Wardle MC, De Wit H. MDMA alters emotional processing and facilitates positive social interaction. Psychopharmacology. 2014;231(21):4219\u201329. https:\/\/doi.org\/10.1007\/s00213-014-3570-x.","journal-title":"Psychopharmacology"},{"issue":"1","key":"1363_CR13","first-page":"136","volume":"290","author":"M Mas","year":"1999","unstructured":"Mas M, Farr\u00e9 M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290(1):136\u201345.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1363_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4161\/23328940.2014.955433","volume":"1","author":"ME Liechti","year":"2014","unstructured":"Liechti ME. Effects of MDMA on body temperature in humans. Temperature. 2014;1(3):192\u2013200. https:\/\/doi.org\/10.4161\/23328940.2014.955433.","journal-title":"Temperature"},{"issue":"5","key":"1363_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.7759\/cureus.15223","volume":"13","author":"S Elkattawy","year":"2021","unstructured":"Elkattawy S, Mowafy A, Younes I, Tucktuck M, Agresti J. Methylenedioxymethamphetamine (MDMA)-induced hyponatremia: case report and literature review. Cureus. 2021;13(5):13\u20136. https:\/\/doi.org\/10.7759\/cureus.15223.","journal-title":"Cureus"},{"key":"1363_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113894","volume":"347","author":"G Costa","year":"2022","unstructured":"Costa G, Golembiowska K. Neurotoxicity of MDMA: main effects and mechanisms. Exp Neurol. 2022;347: 113894.","journal-title":"Exp Neurol"},{"issue":"5","key":"1363_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2174\/138920110791591535","volume":"11","author":"M Carvalho","year":"2010","unstructured":"Carvalho M, Pontes H, Remiao F, Bastos ML, Carvalho F. Mechanisms underlying the hepatotoxic effects of ecstasy. Curr Pharm Biotechnol. 2010;11(5):476\u201395.","journal-title":"Curr Pharm Biotechnol"},{"key":"1363_CR18","unstructured":"Winstock A, Maier LJ, Zhuparris A, et al. Global drug survey (GDS) 2021 key findings report.\u00a02021."},{"issue":"11","key":"1363_CR19","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1111\/add.15493","volume":"116","author":"A Roxburgh","year":"2021","unstructured":"Roxburgh A, Sam B, Kriikku P, et al. Trends in MDMA-related mortality across four countries. Addiction. 2021;116(11):3094\u2013103. https:\/\/doi.org\/10.1111\/add.15493.","journal-title":"Addiction"},{"issue":"5","key":"1363_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"\u2022\u2022 Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat. 2021;78(5):481\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285.","journal-title":"JAMA Psychiat"},{"key":"1363_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/7854","volume":"36","author":"JH Halpern","year":"2018","unstructured":"Halpern JH, Lerner AG, Passie T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Curr Top Behav Neurosci. 2018;36:333\u201360. https:\/\/doi.org\/10.1007\/7854.","journal-title":"Curr Top Behav Neurosci"},{"key":"1363_CR22","unstructured":"Winstock A, Barratt M, Ferris J, Maier L. Global drug survey 2017. Glob Drug Surv. Published online 2017:1-121."},{"key":"1363_CR23","doi-asserted-by":"publisher","unstructured":"Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. 2015;0(0). https:\/\/doi.org\/10.1177\/0269881114565653","DOI":"10.1177\/0269881114565653"},{"key":"1363_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act. Neuropharmacology. 2018;142:143\u201366. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.012.","journal-title":"Neuropharmacology"},{"issue":"9","key":"1363_CR25","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","volume":"236","author":"MC Mithoefer","year":"2019","unstructured":"\u2022 Mithoefer MC, Feduccia AA, Jerome L, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology. 2019;236(9):2735\u201345. https:\/\/doi.org\/10.1007\/s00213-019-05249-5.","journal-title":"Psychopharmacology"},{"key":"1363_CR26","doi-asserted-by":"publisher","unstructured":"\u2022 Wang JB, Lin J, Bedrosian L, et al. Scaling Up: multisite open-label clinical trials of MDMA-assisted therapy for severe posttraumatic stress disorder. J Human Psychol.\u00a02021;1\u201329. https:\/\/doi.org\/10.1177\/00221678211023663","DOI":"10.1177\/00221678211023663"},{"issue":"6","key":"1363_CR27","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"\u2022\u2022 Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025\u201333. https:\/\/doi.org\/10.1038\/s41591-021-01336-3.","journal-title":"Nat Med"},{"issue":"12","key":"1363_CR28","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"\u2022 Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397. https:\/\/doi.org\/10.1177\/0269881116675513.","journal-title":"J Psychopharmacol"},{"issue":"12","key":"1363_CR29","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"\u2022 Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol. 2016;30(12):1165\u201380. https:\/\/doi.org\/10.1177\/0269881116675512.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"1363_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"\u2022 Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry. 2016;3(7):619\u201327. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7.","journal-title":"The Lancet Psychiatry"},{"issue":"11","key":"1363_CR31","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983\u201392. https:\/\/doi.org\/10.1177\/0269881114548296.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"1363_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289\u201399. https:\/\/doi.org\/10.1177\/0269881114565144.","journal-title":"J Psychopharmacol"},{"issue":"11","key":"1363_CR33","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735\u201340. https:\/\/doi.org\/10.4088\/JCP.v67n1110.","journal-title":"J Clin Psychiatry"},{"issue":"15","key":"1363_CR34","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/nejmoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"\u2022 Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402\u201311. https:\/\/doi.org\/10.1056\/nejmoa2032994.","journal-title":"N Engl J Med"},{"issue":"6","key":"1363_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300.Mystical-type","volume":"22","author":"RR Griffiths","year":"2008","unstructured":"Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22(6):621\u201332. https:\/\/doi.org\/10.1177\/0269881108094300.Mystical-type.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"1363_CR36","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4(2):568\u201372. https:\/\/doi.org\/10.1021\/acsptsci.0c00194.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"2","key":"1363_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","volume":"4","author":"DE Olson","year":"2021","unstructured":"Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4(2):563\u20137. https:\/\/doi.org\/10.1021\/acsptsci.0c00192.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"3","key":"1363_CR38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019;71(3):316\u201344. https:\/\/doi.org\/10.1124\/pr.118.017160.","journal-title":"Pharmacol Rev"},{"key":"1363_CR39","doi-asserted-by":"crossref","unstructured":"Goodwin M, Stansfield SC, Hellerstein DJ, Young AH. EM. COMP360 psilocybin therapy in treatment-resistant depression: results from a phase Iib randomized controlled trial. APA Annu Meet Abstr Number 5301, Poster Sess 6. Published online 2022.","DOI":"10.1016\/j.nsa.2022.100213"},{"issue":"3","key":"1363_CR40","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/09687637.2021.1897331","volume":"28","author":"J Thrul","year":"2021","unstructured":"Thrul J, Garcia-Romeu A. Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment. Drugs Educ Prev Policy. 2021;28(3):211\u20134. https:\/\/doi.org\/10.1080\/09687637.2021.1897331.","journal-title":"Drugs Educ Prev Policy"},{"key":"1363_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcbs.2019.11.001","volume":"15","author":"RJ Zeifman","year":"2020","unstructured":"Zeifman RJ, Wagner AC. Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder. J Context Behav Sci. 2020;15:1\u201311. https:\/\/doi.org\/10.1016\/j.jcbs.2019.11.001.","journal-title":"J Context Behav Sci"},{"key":"1363_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.paid.2017.06.004","volume":"117","author":"FS Barrett","year":"2017","unstructured":"Barrett FS, Johnson MW, Griffiths RR. Neuroticism is associated with challenging experiences with psilocybin mushrooms. Pers Individ Dif. 2017;117:155\u201360. https:\/\/doi.org\/10.1016\/j.paid.2017.06.004.","journal-title":"Pers Individ Dif"},{"issue":"NOV","key":"1363_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2018.00897","volume":"9","author":"ECHM Haijen","year":"2018","unstructured":"Haijen ECHM, Kaelen M, Roseman L, et al. Predicting responses to psychedelics: a prospective study. Front Pharmacol. 2018;9(NOV):1\u201320. https:\/\/doi.org\/10.3389\/fphar.2018.00897.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1363_CR44","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1176\/appi.ajp.2020.20030272","volume":"177","author":"AF Schatzberg","year":"2020","unstructured":"Schatzberg AF. Some comments on psychedelic research. Am J Psychiatry. 2020;177(5):368\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20030272.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1363_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1556\/2054.2019.018","volume":"4","author":"T Noorani","year":"2019","unstructured":"Noorani T. Making psychedelics into medicines: the politics and paradoxes of medicalization. J Psychedelic Stud. 2019;4(1):34\u20139. https:\/\/doi.org\/10.1556\/2054.2019.018.","journal-title":"J Psychedelic Stud"},{"issue":"2","key":"1363_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/02791072.2019.1593559.Psychedelic-Assisted","volume":"51","author":"A Trope","year":"2019","unstructured":"Trope A, Anderson BT, Hooker AR, Glick G, Stauffer C, Woolley JD. Psychedelic-assisted group therapy: a systematic review. J Psychoactive Drugs. 2019;51(2):174\u201388. https:\/\/doi.org\/10.1080\/02791072.2019.1593559.Psychedelic-Assisted.","journal-title":"J Psychoactive Drugs"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-022-01363-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-022-01363-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-022-01363-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T19:50:59Z","timestamp":1676836259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11920-022-01363-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1363"],"URL":"https:\/\/doi.org\/10.1007\/s11920-022-01363-y","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"10 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Barber has no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Dr. Aaronson is a consultant to Genomind, LivaNova, Janssen, Neuronetics, and Sage Therapeutics. He also\u00a0receives research support from Compass Pathways and Neuronetics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"As this report does not include original research there is no involvement from the authors in human or animal\u00a0research and informed consent is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}